Substituted azabenzoxazoles

1. A compound represented by Formula I:

or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, wherein:

Y is N;

A is N, or CH;

X is O or S;

Z is selected from the group consisting of benzothiazolyl, indolyl, pyrazolopyridinyl, and pyrrolopyridinyl all optionally substituted with 1 to 3 groups of R 2 , R 3 or R 4 , provided that when R 1 is hydrogen or —(CH 2 ) n halo and Z is benzothiazolyl, then the R 2 , R 3 and R 4 substituents on the benzothiazolyl cannot be hydrogen, —(CH 2 ) n halo, —C 1-6 alkyl, —CF 3 , or —(CH 2 ) n OR;

R represents hydrogen, or —C 1-6 alkyl;

R 1 represents hydrogen, —C 5-10 heterocyclyl, —N(R 2 ) 2 , CN, —(CH 2 ) n halo, CF 3 , —O(CH 2 ) n R, O(CH 2 ) n C 5-10 heterocyclyl, —C 1-6 alkyl, —OCF 3 , —O(CH 2 ) n F, —(O(CH 2 ) s ) p halo, —(O(CH 2 ) s ) p OR, —C(O)OR, or hetero-spirocycle said alkyl, and heterocyclyl optionally substituted with 1 to 3 groups of R a , with the proviso that R 1 , R 2 , R 3 and R 4 are not hydrogen at the same time;

R 2 , R 3 and R 4 independently represent hydrogen, —(CH 2 ) n halo, —C 1-6 alkyl, —CF 3 , —(CH 2 ) n OR, (CH 2 ) n C 5-10 heterocyclyl, —N(R) 2 ,said alkyl, and heterocyclyl optionally substituted with 1 to 3 groups of R a ;

R a represents —CN, NO 2 , halo, CF 3 , —C 1-6 alkyl, —C 1- 6 alkenyl, —C 1-6 alkynyl, —(CH 2 ) n halo, —OR, —NRR 1 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR l COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3, —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 ,or —C(═NOR 1 )R 2 ;

n represents 0-6;

s represents 2-4; and

p represents 1-3.

2. The compound according to claim 1 wherein Z is selected from the group consisting of:

or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof.

3. The compound according to claim 1 wherein R 1 is selected from the group consisting of —C 5-10 heterocyclyl, —N(R 2 ) 2 , —(CH 2 ) n halo, —O(CH 2 ) n C 5-10 heterocyclyl, —(O(CH 2 ) s ) p halo, and —(O(CH 2 ) s ) p OR.

4. The compound according to claim 1 wherein the compounds of formula I are 2 11, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 18 F, 35 S, 36 CL, 82 Br, 76 Br, 77 Br, 123 I, 124 I and 131 I isotopically labeled.

5. The compound according to claim 1 of structural formula Ia:

or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof.

6. The compound according to claim 1 of structural formula Ic:

or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof.

7. A compound which is:

N-(2-methoxyethyl)-2-[4-(methylamino)phenyl][1,3]oxazolo[5,4-b]pyridin-5-amine,

N-methyl-4-[5-(2-methylmorpholin-4-yl)[1,3]oxazolo[5,4-b]pyridin-2-yl]aniline,

N-methyl-4-(5-pyrrolidin-1-yl[1,3]oxazolo[5,4-b]pyridin-2-yl)aniline,

5-fluoro-2-(2-methyl-1,3-benzothiazol-6-yl)[1,3]oxazolo[5,4-b]pyridine,

5-fluoro-2-(1-methyl-1H-indo1-5 -yl)[1,3]oxazolo [5,4-b]pyridine,

2-(1,3-benzothiazol-6-yl)-5-fluoro[1,3]oxazolo[5,4-b]pyridine,

2-(2,3-dimethyl-1H-indol-5-yl)-5-fluoro[1,3]oxazolo[5,4-b]pyridine,

5-fluoro-2-[1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-5-yl][1,3]oxazolo[5,4-b]pyridine,

5-fluoro-2-(1H-indol5-yl)[1,3]oxazolo[5,4-b]pyridine,

5-fluoro-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)[1,3]oxazolo[5,4-b]pyridine,

[5-(5-Fluoro-oxazolo[5,4-b]pyridin-2-yl)-pyridin-2-yl]-methyl-amine,

[5-(5-Fluoro-oxazolo[5,4-b]pyridin-2-yl)-pyridin-2-yl]-dimethyl-amine,

5-Fluoro-2-(6-[1,2,4]triazol-1-yl-pyridin-3-yl)-oxazolo[5,4-b]pyridine,

5-Fluoro-2-(1-methyl-1H-pyrrolo [2,3 -b]pyridin-5 -yl)-oxazolo [5,4-b]pyridine,

5-chloro-2-(1-methyl-1H-pyrrolo [2,3 -b]pyridin-5 -yl)-oxazolo [5,4-b]pyridine,

5-Fluoro-2-[(3-methyl-3H-imidazol-4-yl)-pyridin-3-yl]-oxazolo[5,4-b]pyridine,

[5-(5 -Fluoro-oxazolo[5,4-b]pyridin-2-yl)-3 -methyl-pyridin-2-yl]-methyl-amine,

5-Fluoro-2-(1-methyl-1H-indazol-5-yl)-oxazolo[5,4-b]pyridine,

5-Fluoro-2-(1H-indo-6-yl)-oxazolo[5,4-b]pyridine,

5-Fluoro-2-(1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine,

2-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-5-fluoro-oxazolo[5,4-b]pyridine,

5-Fluoro-2-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine,

2-(3-Bromo-imidazo[1,2-a]pyridin-7-yl)-5-fluoro-oxazolo[5,4-b]pyridine,

5-Fluoro-2-(3-fluoro-1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine,

5-Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-thiazolo[5,4-b]pyridine,

b 5 -Fluoro-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-thiazolo[5,4-b]pyridine,

or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof.

8. The compound according to claim 7 which isotopically labeled as 11 C, 13 C, 14 C, 18 F, 15 O, 13 N, 35 S, 2 H, 3 H.

9. The compound according to claim 7 which is 5-fluoro-2-(1H-indol-5-yl)[1,3]oxazolo[5,4-b]pyridine; or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof.

10. The compound according to claim 7 which is 5-fluoro-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)[1,3]oxazolo[5,4-b]pyridine; or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof.

11. The compound according to claim 7 which is 5-Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine; or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof.

12. The compound according to claim 7 which is 5-chloro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine; or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof.

13. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.